Features of management and vaccination of comorbid patients with rheumatic diseases in a pandemic of a new coronavirus infection

Abstract

The review presents the results of scientific studies devoted to the features of the course and outcomes of a new coronavirus infection COVID-19 in patients with immuno-inflammatory rheumatic diseases (IIRD). It was noted that the risk of developing COVID-19 for patients with IVR, apparently, is similar to the population or slightly increased and mostly depends on the presence of established risk factors for its severe course (old age, obesity, diabetes mellitus, cardiovascular diseases). Patients receiving long-term immunosuppressive therapy and high doses of glucocorticoids may have a long period of positive viral replication and isolation of a viable virus, which requires dynamic monitoring of such patients and correction of anti-rheumatic therapy. The issues of post-COVID-19 joint syndrome, which can occur within the framework of post-viral arthritis or be the debut of an immuno-inflammatory rheumatic disease, are highlighted. The draft recommendations of the All-Russian Public Organization “Association of Rheumatologists of Russia” on the management and temporary recommendations of V.A. Nasonova Research Institute of Rheumatology for vaccination of patients with rheumatic diseases in the conditions of the COVID-19 pandemic are presented.

Keywords

rheumatic diseases / new coronavirus infection / post-COVID-19 joint syndrome

References

[1] Belov BS, Muravyova NV, Tarasova GM. COVID-19: Rheumatological aspects. Effective pharmacotherapy. 2020;16(16):18–25. DOI: 10.33978/2307-3586-2020-16-16-18-25

[2] Белов Б.С., Муравьева Н.В., Тарасова Г.М. COVID-19: ревматологические аспекты // Эффективная фармакотерапия. 2020. Т. 16, № 16. С. 18–25. DOI: 10.33978/2307-3586-2020-16-16-18-25

[3] Nasonov EL. Rossiiskie klinicheskie rekomendatsii. Revmatologiya. Moscow; 2018. P. 113–141. (In Russ.)

[4] Насонов Е.Л. Российские клинические рекомендации. Ревматология. М., 2018. С. 113–141.

[5] Richman DD, Whitley RJ, Hayden FG. Clinical Virology, 4th ed. Washington: ASM Press; 2016.

[6] Richman D.D., Whitley R.J., Hayden F.G. Clinical Virology. 4th ed. Washington: ASM Press, 2016.

[7] Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8 Suppl(Suppl 1):S9–14. DOI: 10.1046/j.1440-1843.2003.00518.x

[8] Chan-Yeung M., Xu R.H. SARS: epidemiology // Respirology. 2003. Vol. 8 Suppl (Suppl 1). P. S9–14. DOI: 10.1046/j.1440-1843.2003.00518.x

[9] Middle East Respiratory Syndrome Coronavirus [Internet]. Available from: https://www.who.int/emergencies/mers-cov/en/. Accessed: Feb 16, 2020.

[10] Middle East Respiratory Syndrome Coronavirus [Электронный ресурс]. Режим доступа: https://www.who.int/emergencies/mers-cov/en/. Дата обращения: 16.02. 2020.

[11] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020;92(4):401–402. DOI: 10.1002/jmv.25678

[12] Lu H., Stratton C.W., Tang Y.W. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle // J. Med. Virol. 2020. Vol. 92, No. 4. P. 401–402. DOI: 10.1002/jmv.25678

[13] Coronavirus disease 2019 (COVID-19) Situation Report–52 [Internet]. WHO. Available from: https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_2. Accessed: Sep 11, 2021.

[14] Coronavirus disease 2019 (COVID-19) Situation Report – 52 [Электронный ресурс] // WHO. Режим доступа: https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_2. Дата обращения: 5.03.2020.

[15] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. DOI: 10.1016/S0140-6736(20)30251-8

[16] Lu R., Zhao X., Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding // Lancet. 2020. Vol. 395, No. 10224. P. 565–574. DOI: 10.1016/S0140-6736(20)30251-8

[17] Coronavirus disease (COVID-2019) situation reports. 2020 [Internet]. WHO. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed: Mar 5, 2020.

[18] Coronavirus disease (COVID-2019) situation reports [Электронный ресурс] // WHO. Режим доступа: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Дата обращения: 5.03. 2020.

[19] Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronaviruses: the species and its virus – a statement of the Coronavirus Study Group. bioRvxiv. 2020. DOI: 10.1101/2020.02.07.937862

[20] Gorbalenya A.E., Baker S.C., Baric R.S. et al. Severe acute respiratory syndrome-related coronaviruses: the species and its virus – a statement of the Coronavirus Study Group // bioRvxiv. 2020. DOI: 10.1101/2020.02.07.937862

[21] Joo YB, Lim YH, Kim KJ, et al. Respiratory viral infections and the risk of rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):199. DOI: 10.1186/s13075-019-1977-9

[22] Joo Y.B., Lim Y.H., Kim K.J. et al. Respiratory viral infections and the risk of rheumatoid arthritis // Arthritis. Res. Ther. 2019. Vol. 21, No. 1. P. 199. DOI: 10.1186/s13075-019-1977-9

[23] Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–432. DOI: 10.1002/jmv.25685

[24] Li G., Fan Y., Lai Y. et al. Coronavirus infections and immune responses // J. Med. Virol. 2020. Vol. 92, No. 4. P. 424–432. DOI: 10.1002/jmv.25685

[25] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5

[26] Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. 2020. Vol. 395, No. 10223. P. 497–506. DOI: 10.1016/S0140-6736(20)30183-5

[27] Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848. DOI: 10.1007/s00134-020-05991-x

[28] Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China // Intensive Care Med. 2020. Vol. 46, No. 5. P. 846–848. DOI: 10.1007/s00134-020-05991-x

[29] Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann. Rheum. Dis. 2020;79(5):667–668. DOI: 10.1136/annrheumdis-2020-217424

[30] Monti S., Balduzzi S., Delvino P. et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies // Ann. Rheum. Dis. 2020. Vol. 79, No. 5. P. 667–668. DOI: 10.1136/annrheumdis-2020-217424

[31] Tomelleri A, Sartorelli S, Campochiaro C, et al. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Ann Rheum Dis. 2020;79(9):1252–1253. DOI: 10.1136/annrheumdis-2020-217600

[32] Tomelleri A., Sartorelli S., Campochiaro C. et al. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey // Ann. Rheum. Dis. 2020. Vol. 79, No. 9. P. 1252–1253. DOI: 10.1136/annrheumdis-2020-217600

[33] Del Manso M, Andrianou X, Urdiales AM, et al. Integrated surveillance of COVID-19 in Italy outputs and related activities. Epidemiol Prev. 2020;44(5–6 Suppl 2):70–80. (In Italian). DOI: 10.19191/EP20.5-6.S2.105

[34] Del Manso M., Andrianou X., Urdiales A.M. et al. Integrated surveillance of COVID-19 in Italy outputs and related activities // Epidemiol Prev. 2020. Vol. 44, No. 5–6 Suppl 2. P. 70–80. (In Italian). DOI: 10.19191/EP20.5-6.S2.105

[35] Polyanskaya MV. Pnevmoniya u patsientov s revmaticheskimi zabolevaniyami: chastota vstrechaemosti, klinicheskaya kartina, faktory riska [disseretation]. Moscow; 2009. (In Russ.)

[36] Полянская М.В. Пневмония у пациентов с ревматическими заболеваниями: частота встречаемости, клиническая картина, факторы риска: автореф. дис. … канд. мед. наук. М., 2009.

[37] Karateev AE, Amirdzhanova VN, Nasonov EL, et al. “Post-COVID syndrome”: The focus is on musculoskeletal pain. Rheumatology Science and Practice. 2021;59(3):255–262. (In Russ.). DOI: 10.47360/1995-4484-2021-255-262

[38] Каратеев А.Е., Амирджанова В.Н., Насонов Е.Л. и др. «Постковидный синдром»: в центре внимания скелетно-мышечная боль // Научно-практическая ревматология. 2021. Т. 59, № 3. С. 255–262. DOI: 10.47360/1995-4484-2021-255-262

[39] Mazurov VI, Belyaeva IB, Sarantseva LE, et al. Impact of a new coronavirus infection on the clinical course of immunoinflammatory rheumatic diseases. North-West State Medical University named after I.I. Mechnikov. 2021;13(2):39–47. (In Russ.). DOI: 10.17816/mechnikov72269

[40] Мазуров В.И., Беляева И.Б., Саранцева Л.Е. и др. Влияние новой коронавирусной инфекции на клиническое течение иммуновоспалительных ревматических заболеваний // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2021. Т. 13, № 2. С. 39–47. DOI: 10.17816/mechnikov72269

[41] Gasparotto M, Framba V, Piovella C, et al. Post-COVID-19 arthritis: a case report and literature review. Clin Rheumatol. 2021;40(8):3357–3362. DOI: 10.1007/s10067-020-05550-1

[42] Gasparotto M., Framba V., Piovella C. et al. Post-COVID-19 arthritis: a case report and literature review // Clin. Rheumatol. 2021. Vol. 40, No. 8. P. 3357–3362. DOI: 10.1007/s10067-020-05550-1

[43] Derksen VFAM, Kissel T, Lamers-Karnebeek FBG, et al. Onset of rheumatoid arthritis after COVID-19: coincidence or connected? Ann Rheum Dis. 2021;annrheumdis-2021-219859. DOI: 10.1136/annrheumdis-2021-219859

[44] Derksen V.F.A.M., Kissel T., Lamers-Karnebeek F.B.G. et al. Onset of rheumatoid arthritis after COVID-19: coincidence or connected? // Ann. Rheum. Dis. 2021;annrheumdis-2021-219859. DOI: 10.1136/annrheumdis-2021-219859

[45] Fragata I, Mourão AF. Coronavirus Disease 19 (COVID-19) complicated with post-viral arthritis. Acta Reumatol Port. 2020;45(4):278–280.

[46] Fragata I., Mourão A.F. Coronavirus Disease 19 (COVID-19) complicated with post-viral arthritis // Acta Reumatol. Port. 2020. Vol. 45, No. 4. P. 278–280.

[47] Nasonov EL, Lila AM, Mazurov VI, et al. Koronavirusnaya bolezn’ 2019 (COVID-19) i immunovospalitel’nye (autoimmunnye) revmaticheskie zabolevaniya. Proekt rekomendatsii Obshcherossiiskoi obshchestvennoi organizatsii “Assotsiatsiya revmatologov Rossii” [Internet]. (In Russ.). Available from: https://rheumatolog.su/news/koronavirusnaya-bolezn-2019-COVID-19-i-immunovospalitelnye-autoimmunnye-revmaticheskie-zabolevaniya/. Accessed: Sep 25, 2021.

[48] Насонов Е.Л., Лила А.М., Мазуров В.И. и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные (аутоиммунные) ревматические заболевания. Проект рекомендаций Общероссийской общественной организации «Ассоциация ревматологов России» [Электронный ресурс]. Режим доступа: https://rheumatolog.su/news/koronavirusnaya-bolezn-2019-COVID-19-i-immunovospalitelnye-autoimmunnye-revmaticheskie-zabolevaniya/. Дата обращения: 25.09.2021.

[49] O vaktsinatsii protiv SOVID-19 pri immunovospalitel’nykh revmaticheskikh zabolevaniyakh [Internet]. (In Russ.). Available from: https://rheumatolog.su/news/o-vakcinacii-protiv-sOVID-19-pri-immunovospalitelnyh-revmaticheskih-zabolevaniyah/. Accessed: Sep 25, 2021.

[50] О вакцинации против СOVID-19 при иммуновоспалительных ревматических заболеваниях [Электронный ресурс]. Режим доступа: https://rheumatolog.su/news/o-vakcinacii-protiv-sOVID-19-pri-immunovospalitelnyh-revmaticheskih-zabolevaniyah/. Дата обращения: 25.09.2021.

RIGHTS & PERMISSIONS

Belyaeva I.B., Mazurov V.I., Sarantseva L.E., Trofimov E.A.